Publications

Showing 2 of 2 Publications

2024

P-057 Comparative Efficacy of Cilta-Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: A Network Meta-Analysis
Mina R, Khan A, McClune B, Bar N, Caers J, Larsen J, Mendes J, Lee S, Benachour N, Chen D, Zhao M, Lonardi C, Slaughter A, Lengil T, Burnett H, Cichewicz A, Neupane B, Filho O, Dytfeld D, Sidana S. P-057 Comparative Efficacy of Cilta-Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: A Network Meta-Analysis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s74. DOI: 10.1016/s2152-2650(24)01960-8.
Peer-Reviewed Original Research
Concepts

2023

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Bar N, Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Otero P, Bermúdez M, Martin T, Santoro A, Yee A, Creignou M, Rodriguez C, Cerchione C, De La Rubia J, Oriol A, Waibel H, Besemer B, Thompson E, Kiesel B, Chen J, Chung A, Boss I, Gaudy A, Li S, Hsu K, Godwin C, Burgess M, San-Miguel J, Costa L. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study. Blood 2023, 142: 2011. DOI: 10.1182/blood-2023-180013.
Peer-Reviewed Original Research
Concepts

Download Full List